Seminars in arthritis and rheumatism最新文献

{"title":"Is T-cell senescence associated with inflammatory arthritis and disease burden? A systematic review","authors":"Sepehr Qooja ,&nbsp;Matthew J Roberts ,&nbsp;Nastaran Fakher ,&nbsp;Mayada Demashkieh ,&nbsp;Arumugam Moorthy ,&nbsp;Nicolette C Bishop","doi":"10.1016/j.semarthrit.2025.152757","DOIUrl":"10.1016/j.semarthrit.2025.152757","url":null,"abstract":"<div><div>Musculoskeletal and rheumatic diseases, such as rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA), are prevalent and are increasingly common worldwide. The aetiology of these diseases varies; some are linked to mechanical stress (e.g., osteoarthritis), while others, like RA and axSpA, are associated with autoimmune processes. Despite their different origins, these conditions share a common feature in elevated inflammatory profiles compared to healthy populations. In autoimmune diseases, immune cells—particularly T-cells—are chronically activated, and the regulatory system is unable to control this. Chronic activation and proliferation often lead to a state known as cellular senescence. Senescent T-cells develop distinct characteristics, including resistance to apoptosis and the adoption of a pro-inflammatory senescence-associated secretory phenotype (SASP). This phenotype contributes to disease progression by driving the release of pro-inflammatory cytokines and elevating circulating levels of inflammatory markers. This systematic review summarises the results from 20 studies, out of 3203 that were initially picked up by the search phrase, to investigate whether levels of senescent T-cells are correlated with disease burden in the three mentioned conditions (RA, axSpA, and PsA). Our findings indicate that the level of senescent T-cells (T-helper CD4 cells and cytotoxic CD8 T-cells) is higher in patients when compared to healthy populations, and with their altered characteristics, these senescent cells could mechanistically contribute to disease progression, hence symptom burden. However, further investigation is needed in this field to show whether this increased level is associated with disease burden or not.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152757"},"PeriodicalIF":4.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of walking interventions on biomechanical knee osteoarthritis outcomes: A systematic review and meta-analysis","authors":"Aleksandra R. Budarick ,&nbsp;Cheryl L. Hubley-Kozey ,&nbsp;Olga Theou ,&nbsp;William D. Stanish ,&nbsp;Meaghan Hannigan ,&nbsp;Rebecca F. Moyer","doi":"10.1016/j.semarthrit.2025.152755","DOIUrl":"10.1016/j.semarthrit.2025.152755","url":null,"abstract":"<div><h3>Purpose</h3><div>To summarize walking parameters specified in biomechanical analyses for knee osteoarthritis populations, determine the biomechanical effects of walking interventions, and explore associations between walking parameters and biomechanical knee osteoarthritis outcomes.</div></div><div><h3>Methods</h3><div>Databases (CINAHL, Embase, PubMED, SportDiscus, Scopus) were searched through October 2024. Experimental studies investigating biomechanical effects of walking interventions on knee osteoarthritis were included. Study quality was assessed using the <em>QualSyst</em> tool. Quantitative meta-analyses calculated Hedge’s g standardized mean differences (SMD) for first peak knee adduction moment (KAM), KAM impulse, peak knee flexion moment (KFM), and gait speed. Meta-regressions investigated the effect of walking parameters (intervention length; duration, frequency, intensity) on outcomes.</div></div><div><h3>Results</h3><div>Eighteen studies were included. Interventions investigated walking for 19.4 (SD=25.9) weeks, at 24.6 (SD=9.7) minutes per session, and 3.2 (SD=1.7) sessions per week. Most interventions specified self-selected intensity. Meta-analyses of 13 studies indicated walking interventions provide a very small increase in first peak KAM (SMD=0.18), no effect on KAM impulse (SMD=-0.01), small increase in peak KFM (adjusted SMD=0.23), and small increase in gait speed (SMD=0.35). Meta-regressions revealed longer interventions were associated with increased KFM (β=0.02), and higher walking frequency with increased gait speed (β=0.37). No other parameters were associated with biomechanical outcomes.</div></div><div><h3>Conclusions</h3><div>Walking interventions elicit minimal-to-no change in discrete biomechanical metrics of joint loading for individuals with mild-to-moderate knee osteoarthritis. Longer walking interventions or more frequent walking may provide additional functional benefit. These results may inform walking guidelines for knee osteoarthritis and predominantly support increased walking without detrimental effects to knee joint health.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152755"},"PeriodicalIF":4.6,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripartum maternal outcomes in individuals with systemic lupus erythematosus in a real-world electronic health record cohort.","authors":"Saad Khan, Fatima Sohail, Hiba Thasleem, Junaid Imran, Maryam Adnan","doi":"10.1016/j.semarthrit.2025.152731","DOIUrl":"https://doi.org/10.1016/j.semarthrit.2025.152731","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":" ","pages":"152731"},"PeriodicalIF":4.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward a more actionable RA-ILD risk model: Insights beyond the KORAIL cohort","authors":"Yang Liu,&nbsp;Ying Liu,&nbsp;Qian Li,&nbsp;Ke Xu","doi":"10.1016/j.semarthrit.2025.152752","DOIUrl":"10.1016/j.semarthrit.2025.152752","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152752"},"PeriodicalIF":4.6,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the correspondence by Xu et al. regarding \"Toward a more actionable RA-ILD risk model\"","authors":"Sung Hae Chang ,&nbsp;Eun Young Lee ,&nbsp;Jeffrey A. Sparks","doi":"10.1016/j.semarthrit.2025.152753","DOIUrl":"10.1016/j.semarthrit.2025.152753","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152753"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining pancreatic damage and symptom burden in IgG4-related autoimmune pancreatitis: A cross-sectional study of 118 patients from a single-center registry","authors":"Guy Katz ,&nbsp;Liam Harvey ,&nbsp;Yasmin G. Hernandez-Barco ,&nbsp;Zachary S. Wallace ,&nbsp;Ana D. Fernandes ,&nbsp;Grace A. McMahon ,&nbsp;Isha Jha ,&nbsp;Aubree E. McMahon ,&nbsp;Cory A. Perugino ,&nbsp;John H. Stone","doi":"10.1016/j.semarthrit.2025.152742","DOIUrl":"10.1016/j.semarthrit.2025.152742","url":null,"abstract":"<div><h3>Objectives</h3><div>Type 1 autoimmune pancreatitis is a common manifestation of IgG4-related disease (IgG4-RD). However, there is a paucity of literature characterizing pancreatic damage and symptom burden in IgG4-RD.</div></div><div><h3>Methods</h3><div>We performed a cross-sectional analysis of patients who fulfilled the ACR/EULAR IgG4-RD Classification Criteria. Disease features and complications were collected by medical record review. A survey regarding symptoms and disease history was distributed to all patients. Characteristics were compared between patients with and without autoimmune pancreatitis.</div></div><div><h3>Results</h3><div>Of 303 patients who fulfilled Classification Criteria at the time of the chart review, 118 (39 %) had evidence of autoimmune pancreatitis. Overt indicators of acute pancreatitis (e.g., abdominal pain, nausea/emesis, elevated serum lipase) each occurred in fewer than 50 % of patients with autoimmune pancreatitis. Diabetes mellitus (DM), exocrine pancreatic insufficiency (EPI), or both were present in 47 %, 48 %, and 21 % of the autoimmune pancreatitis patients, respectively. After encouraging all patients to have fecal elastase measured, 40/49 (82 %) stool samples had low elastase concentrations. 9/118 (8 %) had undergone pancreatic resections before the diagnosis was established. 162/325 (50 %) completed surveys (<em>n</em> = 81 [50 %] with autoimmune pancreatitis). Patients with autoimmune pancreatitis reported a higher burden of abdominal pain, weight loss, and changes in stool than those without (all <em>p</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Despite an often subclinical presentation, autoimmune pancreatitis is associated with EPI, DM, or both in a high percentage of patients with IgG4-RD. While symptomatic acute pancreatitis may not be common, patient-reported symptom burden due to IgG4-related autoimmune pancreatitis or its complications is greater than previously appreciated.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152742"},"PeriodicalIF":4.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variability in phenotype clusters of Behçet’s syndrome: A systematic review","authors":"Betul Macit ,&nbsp;Sinem Nihal Esatoglu ,&nbsp;Kevser Akyuz-Yesilyurt ,&nbsp;Gulen Hatemi","doi":"10.1016/j.semarthrit.2025.152744","DOIUrl":"10.1016/j.semarthrit.2025.152744","url":null,"abstract":"<div><h3>Background</h3><div>Behçet’s syndrome (BS) is a multisystem vasculitis, and distinct clinical phenotypes with clustering of certain organ manifestations were proposed. However, studies from different cohorts have shown variability in the defined phenotypes. This was attributed to geographic and ethnic differences, but different studies from the same country have also shown variability in phenotype clusters. We aimed to explore the variability in clinical phenotype clustering across different countries and cohorts and possible reasons for these.</div></div><div><h3>Methods</h3><div>An electronic search was carried out in PubMed, EMBASE, and Cochrane Library for studies that assessed phenotype clusters in BS cohorts. Two reviewers independently performed the screening of titles, abstracts, and full texts using Covidence.</div></div><div><h3>Results</h3><div>A total of 15 studies that assessed 17 different cohorts were identified. Several differences were identified in the clusters that were reported in these cohorts. Factors that were identified by this systematic review as possible causes of these differences were study design, statistical analysis method (hierarchical cluster analysis vs. factor analysis), patient population (pediatric vs. adult), setting, diagnostic/classification criteria (International Study Group vs. International Criteria for Behçet’s Disease), disease duration, the definition of organ involvement (such as including cerebral sinus thrombosis in nervous system or vascular involvement), ascertainment of manifestations (such as gastrointestinal involvement confirmed by endoscopy or not), and time component for clustering of manifestations.</div></div><div><h3>Conclusion</h3><div>There is important variability in the phenotype clusters that are reported in different studies and this variability seems to stem from methodologic differences between the studies.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152744"},"PeriodicalIF":4.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney outcomes of systemic lupus erythematosus patients treated with SGLT2 inhibitors: A national cohort study","authors":"Iftach Sagy ,&nbsp;ItamarBen Shitrit ,&nbsp;Ran Abuhasira ,&nbsp;Ran Ben David ,&nbsp;Yosef S Haviv ,&nbsp;Oshrat Tayer-Shifman ,&nbsp;Mahmoud Abu-Shakra ,&nbsp;Elad Brav ,&nbsp;Nitzan Burrack ,&nbsp;Lior Zeller","doi":"10.1016/j.semarthrit.2025.152746","DOIUrl":"10.1016/j.semarthrit.2025.152746","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate the impact of SGLT2 inhibitors on the estimated glomerular filtration rate (eGFR) over time in patients with systemic lupus erythematosus (SLE).</div></div><div><h3>Methods</h3><div>This was a retrospective real-world analysis using the Clalit Health Services SLE registry (CHS-SLE registry), a national cohort of 4354 SLE patients. We conducted a two-step propensity-score matching analysis of SLE patients who initiated SGLT2 inhibitors between 2015 and 2022. The primary outcome was the eGFR at 24 months. We also assessed the event-free probability for SGLT2 inhibitor users versus non-users regarding a rapid decline in eGFR, ≥30 % eGFR decline, new-onset end-stage kidney disease (ESKD), and a composite of these outcomes at 24 months. Additionally, we performed subgroup analyses of eGFR changes stratified by baseline patient characteristics.</div></div><div><h3>Results</h3><div>At baseline, 260 SGLT2 inhibitor users were matched with 413 non-users. The baseline eGFR after matching was similar between the two groups (71.0 vs. 70.0 mL/min/1.73 m², <em>p</em> = 0.7). At 24 months, the eGFR was 71.2 mL/min/1.73 m² (95 % CI 69.1–74.9) in the SGLT2 inhibitor users and 65.4 mL/min/1.73 m² (95 % CI 62.5–68.4) in the non-user group (<em>p</em> &lt; 0.001). The use of SGLT2 inhibitors was associated with a reduced risk of developing a rapid decline in eGFR (HR 0.74, 95 % CI 0.59–0.92, <em>p</em> = 0.01), and a reduced risk of developing the composite outcome (HR 0.72, 95 % CI 0.53–0.97, <em>p</em> = 0.03).</div></div><div><h3>Conclusions</h3><div>In SLE patients, exposure to SGLT2 inhibitors was associated with improved kidney function and a reduced risk of developing adverse kidney outcomes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152746"},"PeriodicalIF":4.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144105723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer risk in Sjögren’s disease: A longitudinal cohort study on incidence, predictors, and mortality impact","authors":"Olga Rusinovich-Lovgach ,&nbsp;Zulema Plaza ,&nbsp;Mónica Fernández Castro ,&nbsp;Jose Rosas-Gómez de Salazar ,&nbsp;Victot Manuel Martínez Taboada ,&nbsp;Alejandro Olive ,&nbsp;Raúl Menor Almagro ,&nbsp;Belen Serrano Benavente ,&nbsp;Judit Font Urgelles ,&nbsp;Angel Garcia-Aparicio ,&nbsp;Sara Manrique-Arija ,&nbsp;Jesús Alberto Garcia Vadillo ,&nbsp;Ruth Lopez-Gonzalez ,&nbsp;Javier Narvaez García ,&nbsp;Mª Beatriz Rodriguez Lozano ,&nbsp;Carlos Galisteo ,&nbsp;Jorge Juan Gonzalez Martin ,&nbsp;Paloma Vela Casasempere ,&nbsp;Elena Rabadán ,&nbsp;Antonio Naranjo ,&nbsp;José Luis Andréu Sánchez","doi":"10.1016/j.semarthrit.2025.152743","DOIUrl":"10.1016/j.semarthrit.2025.152743","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aimed to evaluate standardized incidence ratios (SIRs) of overall malignancies, hematologic malignancies and solid tumors in patients with Sjögren’s disease (SjD) compared to the general population. Furthermore, it sought to identify independent predictors of malignancy and quantify the impact of cancer on mortality.</div></div><div><h3>Methods</h3><div>This prospective, multicenter study included 314 patients clinically diagnosed with SjD and fulfilling 2002 American-European Consensus Group criteria, with a median follow-up of 9.5 years. Clinical, demographic, and serological data were collected, along with malignancy incidence and mortality outcomes. SIRs were calculated using GLOBOCAN data. Multivariate Cox regression identified malignancy predictors. The relative risk (RR) of death and the etiologic fraction in exposed individuals (EFE) assessed cancer-related mortality.</div></div><div><h3>Results</h3><div>A total of 22 malignancies (7.01%) were identified, including 11 hematologic malignancies (50%) and 11 solid tumors (50%). The overall cancer risk was increased (SIR: 1.68, 95% CI: 1.68–1.69), with a substantially higher risk for hematologic malignancies (SIR: 3.55, 95% CI: 3.54–3.56) and a moderate increase for solid tumors (SIR: 1.54, 95% CI: 1.53–1.55). All hematologic malignancies were non-Hodgkin lymphomas (NHL). Independent predictors of malignancy included older age, smoking, lymphadenopathy, splenomegaly, and cryoglobulinemia. Cancer was responsible for 23.8% of deaths (RR: 2.21, EFE: 55%).</div></div><div><h3>Conclusions</h3><div>Patients with SjD have an elevated malignancy risk, mainly driven by NHL, while solid tumor risk remains modest. Malignancy was a significant contributor to mortality. These findings underscore the need for better risk stratification and targeted surveillance in high-risk SjD patients for early detection and intervention.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152743"},"PeriodicalIF":4.6,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143929509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of short-term efficacy and toxicity of 2 glucocorticoid bridging strategies in 2 clinical trials in early rheumatoid and undifferentiated arthritis","authors":"J.A. van der Pol ,&nbsp;E.G. Brilman ,&nbsp;P.H.P. de Jong ,&nbsp;A.E.A.M. Weel ,&nbsp;L.R. Lard ,&nbsp;E.T. Molenaar ,&nbsp;T.W.J. Huizinga ,&nbsp;S.A. Bergstra ,&nbsp;C.F. Allaart","doi":"10.1016/j.semarthrit.2025.152748","DOIUrl":"10.1016/j.semarthrit.2025.152748","url":null,"abstract":"<div><h3>Objectives</h3><div>To compare short-term outcomes of initial methotrexate therapy with higher or lower-dose glucocorticoid (GC) bridging in patients with early rheumatoid or undifferentiated arthritis.</div></div><div><h3>Methods</h3><div>We compared two trials: a ‘higher-dose GC’-study starting with methotrexate and 60 mg/day prednisone, tapered in 7 weeks to 7.5 mg/day (IMPROVED trial) and a ‘lower-dose GC’-study, starting with methotrexate and prednisone 15 mg/day tapered in 10 weeks to nil (arm C of the tREACH trial). After multiple imputation, we compared the DAS and HAQ, rates of DAS-remission (DAS&lt;1.6) and low disease activity (DAS≤2.4) at the first follow-up visit after 3 to 4 months with linear and logistic regression models, adjusted for baseline DAS/HAQ, age, gender, symptom duration, ACPA positivity, BMI and damage.</div></div><div><h3>Results</h3><div>Baseline symptom duration, DAS and HAQ were comparable, but more patients in the lower-dose GC-study arm C fulfilled the 2010 criteria for RA. After correction for confounders, patients in the lower-dose GC-study arm C had a significantly higher DAS (0.62 higher (95 % CI 0.43; 0.80) and HAQ (0.28 higher (95 % CI 0.17; 0.39) at the first follow-up visit compared to patients in the higher-dose GC-study, and less often DAS-remission (63.4 % versus 28.9 %) and low disease activity (80.6 % versus 55.7 %). Fewer adverse events were reported in the higher-dose GC-study.</div></div><div><h3>Conclusion</h3><div>In patients with early RA or UA, a study with higher dosed glucocorticoids as part of initial treatment was associated with significantly better early clinical outcomes compared to a study with lower dosed glucocorticoids, and fewer early side effects. These results should be interpreted with caution due to risk of bias when comparing two distinct clinical trials instead of performing one trial.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"73 ","pages":"Article 152748"},"PeriodicalIF":4.6,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}